article Open AccessTop 10% cited

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

Blood · 1990 · Vol. 76(12) · pp. 2462–2465

H-J Kolb✉(LMU Klinikum)J. Mittermüller(LMU Klinikum)Ch. Clemm(LMU Klinikum)Ernst Holler(LMU Klinikum)Georg Ledderose(LMU Klinikum)G. Brehm(LMU Klinikum)M. U. Heim(LMU Klinikum)W. Wilmanns(LMU Klinikum)

View via DOI Full-text PDF

Abstract

Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with interferon alpha and transfusion of viable donor buffy coat. All had complete hematologic and cytogenetic remission, which persisted 32 to 91 weeks after treatment. In two patients graft-versus-host disease developed and was treated by immunosuppression. These results are an example of adoptive immunotherapy without cytoreductive chemotherapy or radiotherapy in human chimeras.

Hematopoietic Stem Cell Transplantation Chronic Myeloid Leukemia Treatments Polyomavirus and related diseasesMedicineChronic myelogenous leukemiaBuffy coatLeukemiaImmunosuppressionChemotherapyBone marrowImmunotherapyTransplantationGraft-versus-host disease

MeSH terms

AdultBlood TransfusionFemaleGraft vs Host DiseaseHumansImmunosuppressive AgentsInterferon Type IMaleRecurrenceLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBone Marrow TransplantationLeukocyte Transfusion

Citations

1,514

FWCI

6.30

field-weighted impact

References

Percentile

97%

vs. same field & year

Citations per year

Cited by

Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]